MEDRAD, Inc.’s sales revenues grew to $478 million in 2006, an increase of 16 per cent over the previous year. The medical device company has achieved a 15 per cent compounded annual growth in sales for over 10 years.achievedMedrad, Inc.’s sales revenues grew to $478 million in 2006, an increase of 16 per cent over the previous year. The medical device company has achieved a 15 per cent compounded annual growth in sales for over 10 years.

“The medical imaging industry is discovering better ways to detect and treat patients’ disease more accurately and cost effectively, and we remain focused on that goal,” said John P. Friel, president and CEO. “As the population ages, more patients will want to understand their disease and treatment options. Medical imaging provides the data to make informed decisions.”

2006 business highlights include magnetic resonance (MR) product innovations, milestone installations of computed tomography (CT) injection systems, the addition of 180 new positions, and progress on the construction of new Global Center and syringe manufacturing facilities in the Western Pennsylvania region.

MR innovations included the introduction of the Certo™ MR Wireless Network in 2006, which allows Medrad wireless-enabled equipment to travel with the patient from the prep room to the scanner room and then to the recovery area, while maintaining full communication with the remote display on the network. The system allows clinicians to focus less on equipment and more on patient care while efficiently managing patients through the scanner suite. MEDRAD also introduced the first endorectal coil for 3.0T magnetic resonance prostate imaging in 2006. MEDRAD’s full line of eCoils earned a 2006 Product Differentiation Innovation Award from Frost & Sullivan, for unprecedented MR imaging of endorectal regions such as the prostate, colon, bladder, and cervix.

TrackBack URI for this entry

Comments (0)

Subscribe to this comment's feed